PUBLISHER: DelveInsight | PRODUCT CODE: 1125975
PUBLISHER: DelveInsight | PRODUCT CODE: 1125975
"BIVV020 (SAR445088), Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about BIVV020 (SAR445088) for Cold Agglutinin Disease in the 7MM. A detailed picture of the BIVV020 (SAR445088) for Cold Agglutinin Disease in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the BIVV020 (SAR445088) for Cold Agglutinin Disease. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the BIVV020 (SAR445088) market forecast, analysis for Cold Agglutinin Disease in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Cold Agglutinin Disease.
SAR445088 is a humanized IgG4 mAb that binds to and inhibits the Classical Pathway (CP) specific serine protease (C1s), thereby inhibiting CP activity. Activation of the CP of complement is associated with various immune disorders involving the presence of autoantibodies. Inhibition of autoantibody-mediated CP activation on the surface of erythrocytes via C1s binding prevents complement opsonin deposition on red blood cells and protects them from phagocytosis and extravascular hemolysis in autoimmune hemolytic anemia such as Cold Agglutinin Disease (Cold Agglutinin Disease). Inhibition of CP activation via C1s prevents both immune-mediated platelet destruction and inhibition of platelet production caused by anti-platelet autoantibodies (ITP).
SAR445088, a complement inhibitor formerly known as BIVV020, is being developed by the company to treat Cold Agglutinin Disease, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, and Persistent/Chronic Immune Thrombocytopenia (ITP).
The drug is currently being studied in two Phase I (NCT04802057; NCT04269551) studies and is being tested for the treatment of adults with Cold Agglutinin Disease.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
BIVV020 (SAR445088) Analytical Perspective by DelveInsight
This report provides a detailed market assessment of BIVV020 (SAR445088) in Cold Agglutinin Disease in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.
The report provides the clinical trials information of BIVV020 (SAR445088) in Cold Agglutinin Disease covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions